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BACKGROUND: This paper reviews the background to five primary care case-control studies, collectively known as the CAPER studies
(Cancer Prediction in Exeter). These studies, on colorectal, lung, prostate and brain tumours, sought to identify the particular features
of cancer as reported to primary care. They also sought to quantify the risk of cancer for symptoms and primary care investigations,
both individually and paired together.
METHODS: Two studies were on colorectal cancer: the former with 349 cases used hand searching and coding of entries, while the
latter obtained 6442 cases from a national electronic database. The lung and prostate studies had 247 and 217 cases, respectively,
and used manual methods. The brain study also used a national electronic database, which provided 3505 cases.
RESULTS: Generally, the symptoms matched previous series from secondary care, though the risks of cancer, expressed as positive
predictive values, were lower. Rectal bleeding in colorectal cancer, and haemoptysis in lung cancer both had positive predictive values
of 2.4%. The risk of a brain tumour with headache was one in a thousand.
INTERPRETATION: The results identify areas where current guidance on urgent referral for investigation of suspected cancer could
be improved.
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Several papers in this supplement refer to the relatively
poor cancer outcomes in the United Kingdom (Verdecchia et al,
2007). Part of the underperformance relates to delays in
diagnosis, which may account for over 5000 extra deaths annually
(Richards, 2009). Diagnostic delays may be reduced in three main
ways: by screening, by earlier presentation when symptoms are
experienced (the so-called ‘patient delay’), or by better identifica-
tion of cancer in the symptomatic patient. Although screening
reduces mortality in several cancers, current UK programmes will
identify only one-tenth of the total number of UK cancers, leaving
the other 90% to present with symptoms (Goodyear et al, 2008;
Hamilton, 2009). This is usually to primary care (Hamilton and
Peters, 2007).
Despite the importance of cancer as a cause of death, at the level
of the individual general practitioner (GP) it is rare (Summerton,
2002). Every year, a full-time GP will have one patient diagnosed
with each of the four common cancers (breast, lung, colon and
prostate). All other cancers (except skin) are considerably less
common – for instance, a new ovarian cancer is diagnosed every 5
years per GP. Therefore, GPs obtain little personal experience of
cancer diagnosis, although few days will pass without a patient
consulting with a symptom that could represent malignancy. This
is the crux of the problem: how does a GP identify the one patient
with cancer from among the many who do not? The problem can
be split into two interrelated questions. The first is simple: could
this symptom represent cancer? Although almost any symptom
could portend an underlying cancer, in practice GPs use a
relatively short checklist of ‘red-flag’ symptoms. When a patient
describes one of these selected symptoms, the second question is
how likely is cancer? Symptoms may pass the first test, but often
fail the second. For example, GPs know that constipation is a
symptom of colorectal cancer, yet rarely actually investigate for it,
as the risk of cancer is deemed to be too small to warrant testing.
This is the rationale for national guidance, particularly that from
the National Institute for Health and Clinical Excellence (NICE,
2005). However, the evidence base for such guidance was poor, at
least in terms of primary care studies (Hamilton and Sharp, 2004).
To address these two practical primary care questions, a series
of studies was designed, with two main objectives: to identify
symptoms of common cancers that are presented to primary care,
and to quantify these symptoms. These studies mostly took place
in Exeter, Devon, UK, and thus the acronym CAPER was chosen,
standing for Cancer Prediction in Exeter. Five studies have been
completed, and are published. They relate to colorectal (Hamilton
et al, 2005b), lung (Hamilton et al, 2005a), prostate (Hamilton
et al, 2006) and brain tumours (Hamilton and Kernick, 2007), with
the fifth repeating colorectal, but focussing on anaemia (Hamilton
et al, 2008). A sixth, on ovarian cancer has recently been published
(Hamilton et al, 2009b). A seventh study, on the features of metastatic
cancer, has begun.
MATERIALS AND METHODS
Study design
The gold standard method of identifying and quantifying the risk
of cancer (or any outcome) associated with a symptom is a
prospective study. A conventional prospective study would be *Correspondence: Dr W Hamilton; E-mail: w.hamilton@bristol.ac.uk
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www.bjcancer.comimpossibly large to conduct in primary care, given the relative
frequency of symptoms, coupled to the relative rarity of new
cancer diagnoses. Furthermore, the list of symptoms for study
would have to be determined in advance, meaning any previously
unrecognised diagnostic feature of cancer would be missed. For
the CAPER studies, case-control methods were chosen. The main
concern with such studies is the potential bias from patient recall.
Patients interviewed after diagnosis may remember features they
consider to be important, whereas the comparison group, who may
have had similar symptoms, may not retain such memories. This
bias can be eliminated by using data collected before the diagnosis
was made – in this case using GP records.
Case identification and control generation
For the first three studies (henceforth called the Exeter studies),
cases were identified from the local cancer registry, supplemented
by computerised searches at each participating surgery. Once the
inclusion and exclusion criteria were applied (these largely related
to doubtful diagnoses, or to missing records) five age-, sex- and
practice-matched controls were generated from the doctors’
computers. Controls who had not consulted in the 2 years before
the diagnosis date of their matched case were rejected. Similar
methods were used in the two national electronic database studies
(henceforth called the electronic studies), other than the cases
being identified by searches on the GP records, and seven controls
being available (this being the standard number offered by the
databases).
The entire medical record for 2 years was coded by trained
research assistants using the International Classification of
Primary Care-2 – the most symptom-based of the coding systems
(Okkes et al, 2002). In the electronic studies, only 1 year of records
was examined, and pre-selected symptoms were identified.
Analytical methods
The studies had similar analytical methods. All variables associated
with cancer in univariable conditional logistic regressions (usually
around 100 variables) entered multivariable analyses. The multi-
variable analyses generally reduced the number of variables to
around 10, all of which were independently associated with cancer,
mostly at a P-value o0.001. For these features, a univariable
likelihood ratio was calculated.
Note: Likelihood ratio: This is simpler than it sounds. This is the
chance of a patient with cancer having a symptom of the cancer,
divided by the chance of a patient without cancer having the same
symptom. For example, in lung cancer, 20% of cases had reported
haemoptysis, whereas 1.5% of controls had done so. Thus, the
positive likelihood ratio was 20/1.5¼13.
Positive predictive value: This is the chance of a patient having
the disease of interest when they have reported the symptom. For
the same example, a person reporting haemoptysis to their GP has
a 2.4% chance of the symptom being due to an underlying lung
cancer.
There is a relationship between these two metrics. The positive
predictive value (PPV) for the symptom is the annual incidence of
the relevant cancer multiplied by the likelihood ratio for the
symptom. Strictly, it is slightly more complicated than that, in that
the PPV and the incidence have to be expressed as odds for
the calculations, and then converted back to percentages, but the
essential point is that the larger the likelihood ratio, the higher the
positive predictive value.
From this likelihood ratio, and using the incidence of cancer and
Bayes’ theorem, a PPV for each variable could be calculated
(Knottnerus, 2002). Calculation of positive predictive values was
then repeated using pairs of symptoms, and in different strata,
where the size of the databases allowed it.
RESULTS
Details of the data sources for the studies are summarised in
Table 1. Identification of cases in the Exeter studies was generally
straightforward, with a high percentage of cases supported by
histological proof. This was not available for the two electronic
studies. The incidence of cancer in the Exeter studies was very
similar to national figures, whereas it was slightly below national
figures for the electronic studies, suggesting that some cancer
diagnoses were missing from the electronic databases. In all
studies, the age ranges were similar to national figures.
Consultation rates and symptom reporting were significantly
higher for cases before diagnosis, particularly in the 6 months
immediately before diagnosis. The symptoms independently
associated with cancer after the multivariable analyses are
summarised in Table 2. These are ranked by likelihood ratio,
showing that the symptom with the strongest association with
cancer is not necessarily the most common symptom in cases.
Lung cancer symptoms had markedly lower likelihood ratios when
compared with the other cancers – other than that for
haemoptysis. This reflected the frequency of lung cancer
symptoms in the non-cancer population. Thus, 65% of lung
cancer cases had reported cough (with 43% reporting it a second,
and 28% a third time before diagnosis), yet the likelihood ratios
remained very low. Even lower was the risk of a brain tumour in a
patient presenting to primary care with a new-onset headache, at
one in a thousand.
Abnormal primary care investigations are summarised in
Table 3. No primary care tests were found to be associated with
brain tumours. The risk of colorectal cancer with anaemia was very
high for the values recommended by NICE as warranting referral: a
haemoglobin value of o10gdl
 1 in women equating to an 8% risk,
and of o11gdl
 1 in men, a 13% risk (Hamilton et al, 2008).
Three unexpected associations were noted: between a raised
glucose level and colorectal cancer, between thrombocytosis and
lung cancer, and between impotence and prostate cancer. Diabetes
is a well-accepted risk factor for colorectal cancer (Larsson et al,
2005). Even so, it was a surprise that a raised blood sugar remained
significant in the final multivariable models including symptoms.
Thrombocytosis as a feature of lung cancer had been described
Table 1 Details of data sources for the CAPER studies
Colorectal Lung Prostate Brain Colorectal (anaemia)
Data source Direct from GP surgeries, including paper and computerised records GPRD electronic THIN electronic
Geography All 19 Exeter practices UK sample UK sample
Year of diagnosis 1998–2002 1988–2006 2000–2006
Age range (years) 40 and over 18 and over 30 and over
Population size 60500 Up to 4000000 Approx. 2200000
Number of cases 349 247 217 3505 3183
Abbreviations: GP¼general practitioner; CAPER¼Cancer Prediction in Exeter; GPRD¼General Practice Research Database.
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British Journal of Cancer (2009) 101(S2), S80–S86 & 2009 Cancer Research UKTable 2 Symptoms of cancer recorded in primary care, their prevalence in cases (%) and their likelihood ratios (LR)
Colorectal cancer Prostate cancer Lung cancer Brain tumours
Symptom % LR Symptom % LR Symptom % LR Symptom % LR
Rectal bleeding 42 10 Urinary retention 15 9 Haemoptysis 20 13 New seizure 4 96
Loss of weight 27 5.1 Hesitancy 17 9 Loss of weight 27 6 Motor loss 9 21
Abdominal pain 42 4.5 Impotence 31 9 Loss of appetite 19 5 Confusion 3 16
Diarrhoea 38 3.9 Frequency 47 7 Dyspnoea 56 4 Weakness 3 11
Constipation 26 1.8 Nocturia 29 6 Chest or rib pain 42 3 Headache 10 7
Haematuria 15 3 Fatigue 35 2 Memory loss 1 3
Loss of weight 10 2 Cough 65 2 Visual disorder 1 3
Note: The first column shows the percentage of cases with the symptom recorded in their notes before diagnosis, and the second column is the positive likelihood ratio. For
simplicity, all figures have been rounded to integers.
Table 3 Abnormal primary care investigations for cancer, their prevalence in cases (%) and their likelihood ratios (LR)
Anaemia in colorectal cancer
Colorectal cancer Prostate cancer Lung cancer Males Females
Result % LR Result % LR Result % LR
Haemoglobin
(gdl
 1) % LR % LR
Positive FOB 9 31 PSA44ngml
 1 61 29 Thrombocytosis 14 19 o9.0 5 27 7 43
Haemoglobin 12–12.9gdl
 1 5 4 PSA42ngml
 1 61 19 Abnormal spirometry 10 14 9.0–9.9 4 17 5 12
Haemoglobin 10–11.9gdl
 1 11 4 10.0–10.9 4 7 8 7
Haemoglobin o10gdl
 1 12 10 11.0–11.9 5 4 8 3
Blood sugar410mmoll
 1 7 3 12.0–12.9 6 3 10 2
Abbreviation: PSA¼prostate-specific antigen.
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5.3
4.5 8.5 3.6 3.2  Rectal bleeding 
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2.6
3.4
2.1,
6.0
6.4 7.4 1.3
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2.6
4.7  Loss of weight 
3.0
1.8,
5.2
1.4
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2.2
3.3 2.2
1.1,
4.5
6.9  Abdominal pain 
1.7
0.8,
3.7
5.8 2.7 >10 Abdominal 
tenderness 
Figure 1 Positive predictive values (%) for colorectal cancer for individual features, repeat presentations and for pairs of features (in the context of a
background risk of 0.25%). Notes: (1) The top row (bold) gives the PPV for an individual feature. The cells along the diagonal relate to the PPV when the
same feature has been reported twice. Thus, the constipation/constipation intersect is the PPV for colorectal cancer when a patient has attended twice (or
more often) with constipation. Other cells show the PPV when a patient has two different features. (2) The top figure in each cell is the PPV. It has only been
calculated when a minimum of 10 cases had the feature or combination of features. The two other figures are the 95% confidence intervals (CIs) for the
PPV. These have not been calculated when any cell in the 2 2 table was below 10. For haemoglobin o10gdl
 1 with abdominal tenderness, no controls had
this pair. It was scored as a PPV of 410%. (3) The yellow shading is when the PPV is above 1%. The amber shading is when the PPV is above 2%, which
approximates to a risk of colorectal cancer of eight times normal. The red shading is for PPVs above 5.0% approximating to a risk of 20 times normal.
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for possible cancer, but not previously in primary care (Pedersen
and Milman, 2003). Finally, impotence was found to have a strong
association with a future diagnosis of prostate cancer, with a PPV
of 3%, a previously unreported finding.
Positive predictive values were calculated for individual
symptoms, pairs of symptoms and symptoms reported for a
second time in primary care. These values are shown in Figure 1
(colorectal), Figure 2 (lung), Figure 3 (prostate), and Figures 4 and
5 (anaemia).
DISCUSSION
The five studies largely confirmed that the symptoms of cancer
listed in medical textbooks were relevant in primary care, and were
often reported months before diagnosis. The new information was
the relative importance of the symptoms, and the risk of cancer
posed by each one. Current UK referral guidance suggests
particular symptoms for urgent referral, without any explicit
rationale given for the choice. Now there are risk estimates for the
symptoms of some common cancers, the choice of symptoms can
be placed on a stronger footing.
Some important points emerged for individual cancers. For
colorectal cancer, it was clear that a policy of concentrating on
rectal bleeding will only yield a small return, in that only 42% of
cases experience this symptom, and referrals are made quickly
(Barrett et al, 2006). Furthermore, the threshold haemoglobin
values recommended for referral of iron deficiency anaemia
equated to very high risks – at least when compared with the
risks inherent in the other symptoms deemed worthy of referral.
Perhaps the most important concept to arise from the colorectal
studies was the ‘low-risk-but-not-no-risk’ symptom. Most patients
with colorectal cancer never have a high-risk symptom such as
rectal bleeding or severe anaemia. Thus, most do not qualify for
urgent referral, explaining in part why so few colorectal cancers are
diagnosed through the 2-week wait clinics (Thorne et al, 2006; Rai
and Kelly, 2007). Not surprisingly, mortality is highest in patients
whose first symptom is abdominal pain, and lowest in those with
rectal bleeding (Stapley et al, 2006a). Thus, a scoring system – the
CAPER score – has been derived to try and identify those most
at risk of cancer, when they only have a low-risk symptom
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1.8 4.0 3.3 Fatigue
0.88 1.2
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2.0 
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2.0 2.3 4.9 Dyspnoea
0.95
0.7,
1.4 
1.8 
1.0,
3.4 
1.8 
0.9,
3.9 
2.0 1.4 5.0 Chest pain 
1.2 
0.7,
2.3 
2.3 
1.2,
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6.1 1.5 9.2 Loss of weight 
1.7 0.9 2.7 >10 Loss of appetite 
3.6 >10 Thrombocytosis 
>10 Abnormal
spirometry 
17 Haemoptysis 
Figure 2 Positive predictive values (%) for lung cancer for individual risk markers, and for pairs of risk markers in combination (against a background
risk of 0.18%). Notes: (1) The top row (bold) gives the PPV for an individual feature. The cells along the diagonal relate to the PPV when the same feature
has been reported twice. Other cells show the PPV when a patient has two different features. (2) The top figure in each cell is the PPV. It has only been
calculated when a minimum of 10 cases had the feature or combination of features. The two other figures are the 95% CIs for the PPV. These have not been
calculated when any cell in the 2 2 table was below 10. (3) The yellow shading is when the PPV is above 1%. The amber shading is when the PPV
is above 2%. The red shading is for PPVs above 5.0%.
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Group, 2009). It encourages GPs to identify other symptoms when
a patient attends with a low-risk symptom such as diarrhoea, and a
score is derived from the symptom list, plus the haemoglobin level.
Initial modelling in a second data set seems very promising,
suggesting that there may be a way of identifying cancer in those
who are currently not prioritised for investigation.
In lung cancer, a concern was that haemoptysis – this time the
only symptom with a risk above 2% – was also relatively rare.
Thus, to expedite diagnosis of lung cancer, the focus will have to be
on the softer symptoms, such as dyspnoea and cough. The clinical
problem is not so difficult for the GP, however, as chest X-rays are
easily obtained, though there is the small risk of a negative X-ray
even when lung cancer is present (Stapley et al, 2006b).
A similar message emerges for prostate cancer. The symptoms
of cancer are largely the same as those of benign prostatic
hyperplasia – with the exception of impotence. However, the
ability to palpate the target organ by rectal examination makes
diagnostics easier. Furthermore, a prostate-specific antigen (PSA)
test is very good at identifying cancer in a man with lower urinary
tract symptoms – indeed once the PSA result was added to the
symptom models, it was the only feature still associated with
cancer. This fits clinically: in a man with lower urinary tract
symptoms, it is the PSA and the rectal examination that predict
cancer, not the particular symptoms.
Values similar to the CAPER score could be calculated for lung
and prostate cancer. The need for them is not so pressing, when
both cancers have a primary care test with reasonable performance
characteristics (the chest X-ray and PSA test, respectively). Any
scoring system for lung cancer will have to be simpler than filling
in an X-ray request form! It is very likely that the ovarian cancer
results will lead to a scoring system, as the diagnosis appears so
difficult, and the optimum investigation – transvaginal ultrasound
– is not widely available.
In the brain tumour study, the main finding was the tiny 0.1%
risk of a brain tumour with new-onset headache. This matched
clinical experience, though, unfortunately, symptom recording in
the General Practice Research Database (GPRD) was too infrequent
to allow identification of second symptoms accompanying headache
that added up to a high-risk combination.
Much of the above accords with current clinical practice. It was
encouraging to see emerging from the results of these studies
symptoms that were already known, even if the strength of the
association with cancer was previously largely unknown. However,
it is debatable if the clinical community is ready to move wholesale
to a risk-based approach to selecting patients for rapid investiga-
tion. In the United Kingdom, entry to rapid investigation is guided
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Figure 3 Positive predictive values (%) for prostate cancer for individual
features, repeat presentations and for pairs of features (against a background
risk of 0.35%). Notes: (1) The top row (bold) gives the PPV for an individual
feature. The cells along the diagonal relate to the PPV when the same
feature has been reported twice. (2) The top figure in each cell is the PPV.
It has only been calculated when a minimum of 10 cases had the feature or
combination of features. The two other figures are the 95% CIs for the PPV.
These have not been calculated when any cell in the 2 2 table was below
10. (3) The yellow shading is when the PPV is above 1%. The amber shading
is when the PPV is above 2%. The red shading is for PPVs above 5.0%.
Haemoglobin (g dl–1)
Age
(years)
Annual
incidence of
colorectal
cancer in this
age group
(%)
<9.0 9.0
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9.9
10.0
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10.9
11.0
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11.9
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to
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Figure 4 PPV (%) for colorectal cancer of haemoglobin result taken in
primary care, in males by age (with 95% CIs). Note: Incidence data, Cancer
Research UK, 2003.
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Figure 5 PPV (%) for colorectal cancer of haemoglobin result taken in
primary care, in females by age (with 95% CIs). Note: Incidence data,
Cancer Research UK, 2003.
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assessment schema. Should these new results simply be used to
improve such guidance? This would certainly help, although there
are many other aspects to primary care cancer diagnosis that are
simply too subtle to be captured by research of this nature, let
alone be expressed as a number. Furthermore, tricky decisions still
need to be made about what level of risk warrants rapid investiga-
tion, and what doctors should do when they suspect cancer even
though their patient does not fit guidance (Hamilton, 2009).
Nonetheless, having a numerical value of risk of cancer can be
helpful clinically, and is one step forward. Additionally, decision
aids derived from work of this nature may be valuable, with
a possibility of these being automated. It is technically feasible
to programme practice computers to spot combinations of
symptoms and alert the GP to a possible diagnosis, potentially
allowing earlier diagnosis.
The future
If we accept that risk estimates for primary care symptoms and
cancer are valuable, then some logical conclusions can be drawn.
There are 18 cancer sites with incidences over 50 new cases per
million population each year. Of the four common ones, only
breast is unstudied; of the medium incidence ones, ovary, uterus,
lymphoma, melanoma and bladder, only ovary has been studied in
any depth. The (difficult) choice is whether to use GP records
directly as in the Exeter studies, and the recent ovarian study, or
whether to use electronic databases. The latter are cheaper, have
larger numbers and excellent recording of laboratory tests; they
also are simpler in terms of ethical approval. Other teams have
used them very successfully (Lawrenson et al, 2006; Jones et al,
2007). Size is important: it can allow subgroup analyses, such as
the male and female anaemia results, which we have extended to
calculation of age- and sex-dependent predictive values for the
common colorectal cancer symptoms in the anaemia data set
(Hamilton et al, 2009a). However, we found symptom recording to
be better in paper records in a direct comparison (Hamilton et al,
2003). This is particularly important when examining multiple
symptoms. A lesser advantage is the ability to code everything in
the records, allowing unexpected features of cancer to be
identified. However, the number of practices required (we used
39 in ovary) may make direct methods impossible logistically, so in
all likelihood the rarer tumours will have to be studied by
electronic methods.
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